ConvaTec Group PLC (LON:CTEC) Given Consensus Rating of “Buy” by Analysts

Shares of ConvaTec Group PLC (LON:CTEC) have received an average rating of “Buy” from the six analysts that are presently covering the firm, MarketBeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is GBX 307.17 ($3.79).

A number of equities research analysts have commented on CTEC shares. JPMorgan Chase & Co. increased their price target on ConvaTec Group from GBX 300 ($3.71) to GBX 323 ($3.99) and gave the company an “overweight” rating in a research note on Thursday, March 7th. Berenberg Bank increased their price target on ConvaTec Group from GBX 290 ($3.58) to GBX 310 ($3.83) and gave the company a “buy” rating in a research note on Wednesday, March 6th.

ConvaTec Group Trading Down 3.3 %

ConvaTec Group stock opened at GBX 275.60 ($3.40) on Friday. The stock has a 50-day moving average of GBX 274.60 and a two-hundred day moving average of GBX 244.45. The company has a debt-to-equity ratio of 77.53, a quick ratio of 0.96 and a current ratio of 1.62. ConvaTec Group has a one year low of GBX 195.10 ($2.41) and a one year high of GBX 295.20 ($3.65). The stock has a market cap of £5.65 billion, a PE ratio of 5,512.00, a price-to-earnings-growth ratio of 2.40 and a beta of 0.55.

ConvaTec Group Increases Dividend

The company also recently disclosed a dividend, which will be paid on Thursday, May 23rd. Stockholders of record on Thursday, April 25th will be paid a $0.04 dividend. This represents a dividend yield of 1.39%. This is a boost from ConvaTec Group’s previous dividend of $0.02. The ex-dividend date of this dividend is Thursday, April 25th. ConvaTec Group’s dividend payout ratio (DPR) is presently 10,000.00%.

ConvaTec Group Company Profile

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns.